Henry D H, Spivak J L
Graduate Hospital, Philadelphia, Pennsylvania, USA.
Curr Opin Hematol. 1995 Mar;2(2):118-24. doi: 10.1097/00062752-199502020-00003.
Recombinant human erythropoietin has been available for clinical use since 1985. It was an immediate success in treating the anemia of chronic renal failure and has also enjoyed some objective success in the treatment of other anemias in either a therapeutic or prophylactic setting, but the issues of appropriate patient selection and cost-benefit ratios are still unresolved. This review discusses the most recent literature concerning the use of recombinant human erythropoietin for the anemia associated with cancer, HIV infection, myelodysplasia, prematurity, autologous blood transfusion, bone marrow transplantation, and chronic renal failure.
重组人促红细胞生成素自1985年起开始用于临床。它在治疗慢性肾衰竭贫血方面立即取得了成功，并且在治疗其他贫血的治疗或预防方面也取得了一些客观的成功，但合适的患者选择和成本效益比问题仍未得到解决。本综述讨论了有关重组人促红细胞生成素用于治疗与癌症、HIV感染、骨髓增生异常综合征、早产、自体输血、骨髓移植和慢性肾衰竭相关贫血的最新文献。
